A Phase 2 interventional study of Oxfendazole and Albendazole in Trichuris Infection, sponsored by Oxfendazole Development Group. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Oxfendazole Development Group · Phase 2, Interventional, and Treatment
Study cancelled prior to initiation as the Oxfendazole Development Group is collaborating on a similar study being conducted by AB Prisma, NCT4713787
The main objective of this study is to provide data on the efficacy profile of different doses of oxfendazole when used in Trichuris trichiura infection. The drug will be also be examined for efficacy against other common nematodes encountered in man (Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus). The study will also provide data on the safety and tolerability of the oxfendazole in patients.
This is an assessor blind, randomized, comparative study in adult patients with proven intestinal infection with Trichuris trichiura to be conducted as a field study. Patients meeting the study entry criteria will receive either 6 mg/kg or 15 mg/kg or 30 mg/kg of oxfendazole as a single oral dose, three single doses of oxfendazole on consecutive days, or albendazole 400mg as a single oral dose. Stool samples will be obtained and examined prior to treatment and at 7, 14 and 21 days after treatment.
30 studies on the registry are indexed under Trichuriasis; 7 are open to participants now.
Browse Trichuriasis studies →This is the only study on the registry with Oxfendazole Development Group as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
Drug: Oxfendazole
Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
Drug: Oxfendazole
Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
Drug: Oxfendazole
Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
Drug: Oxfendazole
Patients receive a single 400 mg/kg dose of albendazole administered orally.
Drug: Albendazole
oral suspension
tablet
cure d14
absence of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients
Time frame: Day 14 of follow up
cure d7
absence of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients
Time frame: Day 7 of follow up
improvement d21
reduction (with respect to the baseline count of that individual) in number of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients
Time frame: Day 21 of follow up
improvement d14
reduction (with respect to the baseline count of that individual) in number of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients
Time frame: Day 14 of follow up
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d7
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Day 7 of follow up
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d14
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Day 14 of follow up
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d21
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Day 21 of follow up
No study locations are listed for this record.
Plan to share: Undecided — The data will be uploaded to the clinicaltrials.gov website, and a publication will be prepared
No publications or documents are linked to this record.
Study cancelled prior to initiation as the Oxfendazole Development Group is collaborating on a similar study being conducted by AB Prisma, NCT4713787
Study cancelled prior to initiation as the Oxfendazole Development Group is collaborating on a similar study being conducted by AB Prisma, NCT4713787
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxfendazole